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Abstract
The objective of the present study was to evaluate whether placental mesenchymal stromal cells (PDMSCs) derived from
normal and preeclamptic (PE) chorionic villous tissue presented differences in their cytokines expression profiles. Moreover,
we investigated the effects of conditioned media from normal and PE-PDMSCs on the expression of pro-inflammatory
Macrophage migration Inhibitory Factor (MIF), Vascular Endothelial Growth Factor (VEGF), soluble FMS-like tyrosine kinase-1
(sFlt-1) and free b-human Chorionic Gonadotropin (bhCG) by normal term villous explants. This information will help to
understand whether anomalies in PE-PDMSCs could cause or contribute to the anomalies typical of preeclampsia.
Methods: Chorionic villous PDMSCs were isolated from severe preeclamptic (n = 12) and physiological control term (n = 12)
placentae. Control and PE-PDMSCs’s cytokines expression profiles were determined by Cytokine Array. Control and PE-
PDMSCs were plated for 72 h and conditioned media (CM) was collected. Physiological villous explants (n = 48) were treated
with control or PE-PDMSCs CM for 72 h and processed for mRNA and protein isolation. MIF, VEGF and sFlt-1 mRNA and
protein expression were analyzed by Real Time PCR and Western Blot respectively. Free bhCG was assessed by
immunofluorescent.
Results: Cytokine array showed increased release of pro-inflammatory cytokines by PE relative to control PDMSCs.
Physiological explants treated with PE-PDMSCs CM showed significantly increased MIF and sFlt-1 expression relative to
untreated and control PDMSCs CM explants. Interestingly, both control and PE-PDMSCs media induced VEGF mRNA
increase while only normal PDMSCs media promoted VEGF protein accumulation. PE-PDMSCs CM explants released
significantly increased amounts of free bhCG relative to normal PDMSCs CM ones.
Conclusions: Herein, we reported elevated production of pro-inflammatory cytokines by PE-PDMSCs. Importantly, PE
PDMSCs induced a PE-like phenotype in physiological villous explants. Our data clearly depict chorionic mesenchymal
stromal cells as central players in placental physiopathology, thus opening to new intriguing perspectives for the treatment
of human placental-related disorders as preeclampsia.
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Introduction
Preeclampsia (PE) is a severe placenta-related syndrome
exclusive of human pregnancy that represents the main cause
of feto-maternal mortality and morbidity worldwide [1,2]. PE
affects 5–10% of all pregnancies [1,2] and, despite intensive
investigation over the past decade, its etiopathogenesis still
remains elusive. Clinical features of preeclampsia are severe
maternal hypertension accompanied by maternal and placental
exacerbated inflammatory response and generalized endothelial
damage [3,4]. Even though PE resolves with placenta removal,
it may cause long term complications as hypertension,
cardiovascular diseases, metabolic and neurological disorders
for both the mother and the newborn [5]. PE clinical symptoms
become evident in the third trimester of pregnancy, but it is
widely believed that they originate from anomalies in placenta
development earlier on during first trimester. The PE placenta
is characterized by immature trophoblast phenotype with
shallow invasion of maternal spiral arteries and impaired villous
vasculogenesis [6]. These aberrations lead to reduced utero-
placental perfusion and placental ischemia, with consequent
increased systemic release of pro-inflammatory cytokines and
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anti-angiogenic factors that promote endothelial cells activation
and damage [6,7,8,9]. Maternal immune maladaptation towards
the feto-placental district has been implicated as a possible cause
for the defective trophoblast development and related maternal-
placental pathological anomalies.
The trophoblast is generally considered the main placental site
of the morphological and molecular alterations responsible for the
onset of preeclampsia. Nevertheless, the human placenta is a
heterogeneous organ composed of several cellular populations
each contributing to the organ physiology. Indeed, beside the
trophoblast, placental villi are composed of endothelial cells and
progenitors, myofibroblasts and mesenchymal stromal cells form-
ing a complex network that concertedly interacts to maintain
placental functionality.
Recently, the human placenta has been identified as source of a
particular type of mesenchymal stromal cells (MSCs) that retain
stem cell-like properties. Placental MSCs (PDMSCs) have been
successfully isolated from the placental basal plate, the amnion and
the decidua. They are characterized by different degrees of
plasticity and possess unique immunologic and immune-regulatory
properties [10,11]. MSCs do not express HLA-DR [12] and have
the ability to suppress the ‘‘mixed lymphocyte reaction’’, thus
being non-immunogenic and exerting an immunosuppressive
effect on T-cells [12]. Recently, amniotic MSCs have been shown
to promote angiogenic growth and to possess anti-inflammatory
and anti-fibrotic activities mediated by the release of specific
trophic factors [13].
MSCs plasticity is of great interest for regenerative medicine
and several groups are exploring the possibilities offered by the
placenta as a new therapeutic tool. On the other hand, the
investigation of placental MSCs immune-modulatory, pro-
angiogenic and anti-inflammatory properties could open new
perspectives into the understanding of placenta-related disorders
due to maternal immune maladaptation and aberrations of
trophoblast development as preeclampsia. The secretion of
cytokines and chemoattractant by the first trimester placenta
with consequent recruitment of lymphocytes, natural killer cells
and macrophages is necessary to maintain proper pregnancy
physiology [14,15,16,17]. Nevertheless, the aberrant production
of inflammatory molecules by placental cells could result in
excessive recruitment of macrophages and immune cells leading
to the abnormal placental development, inflammation and
endothelial dysfunction typical of PE. Indeed, pregnancies
complicated by preeclampsia and Fetal Growth Restriction are
characterized by increased presence of aberrantly-activated
macrophages into the placental bed, data that were correlated
with reduced trophoblast invasion [18].
Our hypothesis is that anomalies in PDMSCs anti-inflamma-
tory and pro-angiogenic properties might cause or contribute to
the defective placental development and/or immune maladap-
tation typical of preeclampsia’’. In the present study, we
characterized cytokine expression profiles of PDMSCs isolated
from the basal plate of normal and severe PE placentae.
Moreover, we investigated the effect of conditioned media from
normal and PE PDMSCs on the expression of Macrophage
migration Inhibitory Factor (MIF), Vascular Endothelial Growth
Factor (VEGF), soluble FMS-like tyrosine kinase-1 (sFlt-1) and
b-human Chorionic Gonadotropin (bhCG) in normal placental
villous explants. MIF is a pro-inflammatory cytokine key player
in PE inflammatory response [19], while VEGF is the main
pro-angiogenic factor sequestered and down-regulated by sFlt-1,
soluble variant of VEGF receptor 1 which aberrant expression
is an hallmark typical of PE [20,21,22,23,24,25]. Thus, we will
determine whether PE PDMSCs could negatively influence
trophoblast inflammatory response and angiogenesis.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of O.I.R.M. S.Anna Hospital and
‘‘Ordine Mauriziano di Torino’’ (n.209; protocol 39226/C.27.1
04/08/09) (Turin, Italy). All patients provided written informed
consent for the collection of samples and subsequent analysis.
Tissue Collection
The study groups included singleton pregnancies complicated
by severe preeclampsia (n = 12) and physiological control term
pregnancies (n = 12). The diagnosis of PE was made according to
the following criteria: presence of pregnancy-induced hypertension
(systolic $140 mmHg, diastolic $90 mmHg) and proteinuria
($300 mg/24 h) after the 20th weeks of gestation in previously
normotensive women [2]. We excluded pregnancies with congen-
ital malformations, chromosomal anomalies (of number and/or
structure) or evident intra uterine infections. Physiological control
placentae were obtained from normal pregnancies that did not
show any signs of preeclampsia or other placental disease. Patients
with diabetes, infections, kidney disease, congenital malformations
and chromosomal anomalies (number and/or structure) were
excluded. Placental villous samples were collected randomly from
the central placental area and snap frozen immediately after
delivery. Calcified, necrotic and visually ischemic areas were
excluded from collection.
Placenta-derived Mesenchymal Stromal Cells (PDMSCs)
Isolation
PDMSCs were isolated by using a protocol modified from
Brooke and colleagues [26]. Immediately after delivery, the
amniotic membranes were mechanically removed and the decidua
was peeled off from the placental basal plate and discharged, in
order to avoid maternal cells contamination. From each control
and PE placenta, 30 grams of tissue were excised from the central
part of placental cotyledons, thus avoiding decidual contamination
from the placental septa, and washed several times with Hank’s
Buffered Salt Solution (HBSS, Gibco, Life Technoligies, Italy) to
remove excess of blood. Next, the placental tissue was mechan-
ically minced and incubated with 100 U/ml collagenase type I
(Gibco, Life Technologies, Italy) plus 5 mg/ml DNAse I (Invitro-
gen by Life Technologies, Italy) for 3 hours. After enzymatic
digestions, the cells were separated by gradient using 1.073 Ficoll
Paque Premium (GE Healthcare Europe, Italy) and the mononu-
clear cells ring was collected, washed and cells were resuspended in
Dulbecco’s modified Minimum Essential Medium (DMEM,
Gibco, Life Technoligies, Italy) supplemented with 10% Fetal
Bovine Serum (FBS Australian origin, Italy) and seeded in T150
flask. Importantly, the culture media was not supplemented with
basic fibroblast growth factor (bFGF) in order to maintain the
original biochemical and molecular features of the placenta-
derived mesenchymal cells. The cultures were maintained at 37uC
and 5% CO2.
PDMSCs Characterization
After passages three to five, the cells were evaluated for specific
mesenchymal stromal cells antigens by flow cytometry. The
following markers were investigated: HLA-DR, CD105, CD166,
CD90, CD34, CD73, CD133, CD20, CD326, CD31, CD45,
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CD14. All the antibodies were purchased from Myltenyi Biotec
(Myltenyi Biotec, Bologna, Italy). Moreover, Oct4 and Nanog
mRNA expression levels were assessed in both control and PE
PDMSCs by semi-quantitative RT PCR in order to verify cellular
stemness. Primers sequences were the following: Oct4 FW(59-
CGT GAA GCTG GAG AAG GAG AAG CTG-39) RV(59-CAA
GGG CCG CAG CTT ACA CAT GTT C-39); Nanog FW(59-
AAT ACC TCA GCC TCC AGC AGA TG-39) RV(59-CTG
CGT CAC ACC ATT GCT ATT CT-39).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
Bromide (MTT) Assay
Normal and preeclamptic PDMSCs proliferation ability was
assessed by MTT assay (Sigma, Italy, Cat.no. M5655). At passage
five, physiological (3 different cell lines) and PE (3 different cell
lines) PDMSCs were seeded in 96-well plates at a density of 6000
cells per well. Each cell lines was plated in six different wells. At
time 0, 48 h and 120 h of culture, cells were incubated with 5 mg/
ml of MTT for 4 h. Next, medium was removed and formazan
salts were dissolved with 100 ml of dimethylsulfoxide (DMSO,
Sigma, Italy Cat. no 000070). 570 nm absorbance at each time
point was determined using a microplate spectrophotomether in
order to establish PDMSCs cell proliferation curve.
Determination of Cellular Senescence
Senescence-associated b-galactosidase (SA-b-gal) nuclear stain-
ing was performed using a SA-b-gal staining kit (Sigma,
Cat.no.CS0030) following manufacturer instructions. At passage
five, normal (two different cell lines) and PE (2 different cell
lines) PDMSCs were plated in 6 well plates at a density of
26105 cells/well in DMEM LG supplemented with 10% FBS.
Each cell line was seeded in six different wells. After 48 h of
culture, the cells were fixed in 1X Fixation Buffer for 6 minutes
and were stained with SA-b-gal–staining solution for 4 h. The
senescent SA-b-gal–positive cells exhibited a blue nuclear color.
Number of positive cells number was determined by phase-
contrast microscopy.
Conditioned Media (CM) Preparation
At passage five, PDMSCs were plated in 6 well plates at a
density of 2.06105 cells/ml (final volume: 2 ml, 46105 cells total).
After 72 h of culture, conditioned media was collected, centri-
fuged, filtered to remove cellular debries and immediately stored at
280uC, while cells were processed for mRNA and protein
isolation.
Cytokines Array
To investigate differences in cytokines production between
normal and preeclamptic PDMSCs, the RayBio Human Cytokine
Antibody Array (#AAH-CYT-5, RayBiotech Inc, GA, USA) was
used. This specific array was chosen because it allows contempo-
rary detection and quantification of eighty different human
cytokines, chemokines and inflammation-related growth factors.
Arrays were performed on unconditioned and conditioned culture
media from normal and PE PDMSCs (prepared as described
above) following manufacturer instructions. Cytokines levels were
quantified by densitometric analysis using ImageQuant software
and normalized by setting the positive controls as 100 and negative
controls as zero percent. The arrays were performed in duplicate
on CMs derived from four normal term PDMSCs lines, four
preeclamptic PDMSCs lines and on unconditioned media (UCM)
as baseline for molecules already present in the culture media.
UCM data were used to normalize Normal and PE PDMSCs CM
results. Cell lines used were all derived from different control and
PE patients.
Human Chorionic Villous Explants Cultures and PDMSCs
Conditioned Media Treatment
Placental biopsies from physiological term placentae were
processed within 2 hours from delivery. Fetal membranes and
decidua were mechanically removed and placental tissues were
washed in phosphate-buffered saline (PBS) solution to remove
excess of blood. Small portions of placental chorionic villi (35 mg,
n = 48) were excised and placed in a 24-well culture dish. Explants
were cultured in Ham’s F12 media (Gibco, Invitrogen by Life
Technologies, Italy) and incubated overnight at 37uC and 5%
CO2 to equilibrate. Next, culture media was removed and
explants were treated for 72 hours with 500 ml of conditioned
media from 4 different control PDMSCs lines (n = 16 explants)
and 4 different PE PDMSCs lines (n = 16 explants). Explants
treated by unconditioned culture media were used as controls
(n = 16 explants). Finally, culture media were collected while
control and treated explants were processed for mRNA and
protein isolation. Each experimental condition was performed in
duplicate.
RNA Isolation and Real Time PCR
Total RNA was extracted from placental MSCs and chorionic
villous explants using TRIZOL reagent according to manufacturer
instructions (Invitrogen by Life Technologies, Italy) and treated
with DNAse I to remove genomic DNA contamination. Two mg of
total RNA was reverse transcribed using random hexamers
approach (Fermentas Europe, St. Leon-Rot., Germany). The
resulting templates were quantified by Real-time PCR (StepO-
neTM Real-Time PCR System, Applied Biosystems, Carlsbad,
California). TaqMan primers and probes for ribosomal 18S, MIF,
VEGF, HCGB, IL-8, IL-6 and TNF-a were purchased from
Applied Biosystems as TaqManH Gene Expression Assays. sFlt-1
primers and probe were designed as previously described by Nevo
and colleagues [23] and purchased from Applied Biosystems as
Custom Gene Expression Assays. For the relative quantitation,
PCR signals were compared among groups after normalization
using 18S as internal reference. Relative expression and fold
change was calculated according to Livak and Schmittgen [27].
Western Blot Analysis
Total proteins were isolated from PDMSCs and chorionic
villous explants using 1X Radio Immuno-precipitation Assay
(RIPA) buffer. Fifty mg of total protein from PDMSCs and villous
explants were processed by SDS-page electrophoresis on 4–12%
polyacrylamide pre-cast gradient gels (Bio-Rad Laboratories S.r.l.,
Italy). Next, proteins were transferred on Polyvinylidene fluoride
(PVDF) membranes and probed at room temperature with
primary antibodies using the SnapID system (Merk-Millipore,
Italy) following manufacturer instructions. Primary antibodies
were: mouse monoclonal anti-human MIF (1:1000 dilution, R&D
Systems, MN, USA), rabbit polyclonal anti-human VEGF (1:1000
dilution, R&D Systems, MN, USA), rabbit polyclonal anti-human
soluble VEGF Receptor (sFlt-1, 1:250 dilution, Life Technologies-
Invitrgen, Italy), rabbit polyclonal anti-human Ki67 (1:500
dilution, Santa Cruz Biotechnologie, USA), goat polyclonal anti-
human Cytokeratin 7 (1:500 dilution, Santa Cruz Biotechnologie,
USA), mouse monoclonal anti-human CD45 (1:500 dilution,
Santa Cruz Biotechnologie, USA) and mouse monoclonal anti-
human CD166 (1:200 dilution, Santa Cruz Biotechnologie, USA).
Biotinylated secondary antibodies were goat anti-mouse for MIF,
Placental Mesenchymal Cells and Preeclampsia
PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e59403
CD45 and CD166 (1:1000 dilution, Vector Laboratories, UK) and
donkey anti-rabbit for VEGF, sFlt-1 and Ki67 (1:1000 dilution,
Vector Laboratories, UK) and donkey anti-goat for Cytokeratin 7
(1:100 dilution, Santa Cruz Biotechnologie, USA). Blots were
visualized using the QDot reagent kit (Invitrogen by Life
Technologies, Italy) following manufacturer instructions.
Free bhCG Assay
Free b hCG released by physiological villous explants treated
with normal or PE PDMSCs conditioned media was measured
using the B?R?A?H?M?S Free bhCG KRYPTOR immunofluo-
rescent assay (Thermo Scientific, Germany) following manufac-
turer instructions.
TNF-a and VEGF Enzyme-linked Immunosorbent Assays
(ELISA)
Concentrations of TNF-a and VEGF proteins in normal and
PE-PDMSCs CM and in protein lysates of CM-treated villous
explants were evaluated by commercially available ELISA kits
(Peprotech), according to the manufacturer’s recommendations.
Values are given as the mean concentration 6 SEM of fourteen
(PDMSCs CM) and twelve (CM-treated villous explants) inde-
pendent experiments, all repeated in duplicate.
Statistical Analysis
All data are represented as mean 6 SE. For comparison of data
between multiple groups we used one-way analysis of variance
(ANOVA) with posthoc Dunnett’s test. For comparison between 2
groups we used paired and unpaired Student’s t-test as appropri-
ate. Statistical test were carried out using Graph Pad Prism 5
statistical software and significance was accepted at P,0.05.
Results
Study Population
Clinical data of the study population are summarized in Table 1.
Seventy-five percent of the babies from severe preeclamptic
pregnancies were growth restricted (Table 1), while 44% of PE
pregnancies were characterized by abnormal Doppler flow
velocity waveforms in the umbilical arteries (AEDF or REDF)
and 88% of them had pathological uterine Doppler.
Placenta-derived Mesenchymal Stem Cells Showed
Proper MSC Antigens Profile
PDMSCs were isolated from both physiological term and
preeclamptic placentae and, starting from passages 3 to 5, they
were characterized for the expression of typical MSCs markers by
flow cytometry. All PDMSCs lines investigated were positive for
CD105, CD166, CD90 and CD73, while they were negative for
HLAII, CD34, CD133, CD20, CD326, CD31, CD45 and CD14
(Fig. S1A), thus showing proper mesenchymal stem cell phenotype
and excluding contamination from trophoblast/epithelial cells and
hematopoietic progenitors. Moreover, all PDMSCs properly
expressed both Oct4 and Nanog mRNA (Fig. S1B).
PDMSCs Isolated from PE Placentae Showed Decreased
Proliferation and Increased Cellular Senescence Relative
to Normal PDMSCs
PDMSCs cell proliferation at 48 h and 120 h was evaluated by
MTT assay. We reported a significant cell proliferation increase in
Normal PDMSCs at both 48 h (p,0.01, 2 Fold Increase) and
120 h (p,0.01, 1.4 Fold Increase vs 48 h, 2.7 Fold Increase vs
time 0), whereas PE PDMSCs showed a slower and not significant
proliferation rate at both 48 h and 12 h (Figure 1). Importantly,
despite Normal and PE PDMSCs had the same cell number at
time 0, cell proliferation at 120 h, as determined by MTT assay,
was significantly increased in Normal vs PE PDMSCs (p,0.01,
1.4 Fold Increase, Figure 1). We next performed senescence-
associated b-galactosidase (SA-b-gal) staining in normal and
preeclamptic PDMSCs. We found significantly increased percent-
age of positive/senescent cells in PE relative to normal PDMSCs
(p,0.01, 3.2 Fold Increase, Figure 2B).
Cytokines Expression Profiles in Conditioned Media from
Normal and Preeclamptic PDMSCs
Mesenchymal stem cells are a promising tool for regenerative
medicine because of their unique immunomodulatory, pro-
vasculogenic and anti-inflammatory properties. Since preeclamp-
Table 1. Clinical Features of the Study Population.
Controls (n=12) Severe Preeclampsia (n =12)
Mean Maternal Age (yr) 32.464.72 34.7565.59
Mean Gestational Age at delivery
[wk (range)]
39.7760.85 (38–41) 32.9663.97 (28–41)
Blood Pressure (mmHg) Systolic: 123611.83 Systolic: 151617.99
Diastolic: 7769.77 Diastolic: 91.41611.56
Proteinuria (g/24 h) Absent 1.4062.16
Fetal Weight (g) A.G.A. (n = 12): 3671.56345.29 A.G.A.(n = 3): 271061411.70
IUGR (n = 9): 1204.776473.74
IUGR 0% 75%
A/REDF (% of women) 0% 44%
Pathological Uterine Doppler R.I 0% 88%
Fetal Sex Males = 70% Males = 41%
Females = 30% Females = 59%
Mode of delivery CS 45% CS 83%
A.G.A.: Appropriate for Gestational Age; IUGR: Intra Uterine Growth Restriction; CS: Caesarean Section.
doi:10.1371/journal.pone.0059403.t001
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sia is characterized by an exacerbated feto-maternal inflammatory
response accompanied by generalized endothelial damage and
aberrant placental vascular development, we investigated whether
PDMSCs derived from normal and PE placentae showed
differences in cytokines production profiles. These data would
help us to understand whether or not PDMSCs could contribute to
physiological placenta development and/or to the aberrant
placentation and inflammatory response typical of PE. To reach
our goal, we performed a cytokine array able to detect 80 different
cytokines (Table S1) present in the conditioned media of both
control and PE PDMSCs. Cytokines expression levels in Normal
and PE PDMSCs conditioned media were compared to positive
and negative standards (used as 100% and 0% expression ranges
respectively) (Figure 3A). The results reported in Table S1 and in
Figure 3 clearly demonstrated that PDMSCs from normal and PE
placentae posses different cytokine expression profiles. Interleukine
8 (IL-8), Interleukine 6 (IL_6), Epithelial neutrophil-activating
protein 78 (ENA-78), Transforming Growth Factor-b2 (TGF-b2),
Monocyte Chemotactic Protein-1 (MCP-1), Tissue Inhibitor of
Metalloproteinases-2 (TIMP-2), Brain-derived neurotrophic factor
(BDNF), Vascular Endothelial Growth Factor (VEGF), Angio-
genin, IGF binding protein 4 (IGFBP-4), Macrophage Inflamma-
tory Protein-1b (MIP-1b), Platelet-derived Growth Factor BB
(PDGF-BB), MCP-3, Thymus and Activation Regulated Chemo-
kine (TARC), Tumor Necrosis Factor-a (TNF-a), Leptin, Fibro-
blast Growth Factor-9 (FGF-9), Osteopontin, and Osteoprotegerin
were dramatically more abundant (differences higher than 19%) in
PE relative to Normal PDMSCs conditioned media.
In addition, Interferon-inducible protein-10 (IP-10), Leukemia
inhibitory factor (LIF), Neurotrophin-3 (NT-3), Neutrophil-acti-
vating Protein-2 (NAP-2), Macrophage-migration Inhibitory
Factor (MIF), Placental Growth Factor (PlGF) and Pulmonary
and Activation-regulated Chemokine (PARC) were markedly
increased (range of increase: 8–19%) in preeclamptic PDMSCs
conditioned media (Figure 3, Table S1).
Furthermore, we performed Real Time PCR analysis on
normal and PE-PDMSCs in order to confirm increased expression
of IL-8, IL-6, MIF, TNF-a and VEGF as detected by Cytokine
Array analysis (Figure S2). We selected this specific pool of
molecules because they represent key players in PE pathogenesis
(MIF, TNF-a and VEGF) and the main pro-inflammatory
cytokines over-expressed by PE-PDMSCs (IL-8 and IL-6). We
found significantly increased expression of MIF (p,0.001, 2.9
Fold Increase), VEGF (p,0.01, 1.9 Fold Increase), TNF-a
(p,0.01, 2 Fold Increase), IL-8 (p = 0.02, 2.3 Fold Increase) and
IL-6 (p = 0.02, 2.2 Fold Increase), thus confirming Cytokine Array
results (Figure S2). Finally, we further corroborated our findings
on PE-PDMSCs increased TNF-a and VEGF protein release by
using specific ELISA assays. We found that PE-PDMSCs CM
contains significantly higher concentrations of both TNF-a
(p,0.01, 34 Fold Increase) and VEGF (p= 0.02, 1.55 Fold
Increase) molecules relative to normal PDMSCs CM (Figure S3A).
Conditioned Media from Preeclamptic PDMSCs Induced
MIF, VEGF, sFlt-1 and Ki67 Over-expression in
Physiological Human Villous Explants
Since we determined that preeclamptic PDMSCs released
augmented concentrations of pro-inflammatory cytokines and
chemotactic factors, we next investigated whether they were
able to negatively influence inflammation and/or vasculogenesis
on the placental tissue. To reach our goal, we treated term
physiological chorionic villous explants with conditioned media
from normal and PE PDMSCs. As markers of inflammation
and vasculogenesis, we investigated MIF and VEGF expression.
We found significantly increased MIF mRNA expression levels
(p = 0.033, 1.75 Fold Increase) in PE PDMSCs CM explants
relative to both untreated controls and explants treated with
normal PDMSCs conditioned media (Figure 4A, left panel).
Results were confirmed at the protein levels where we described
significantly increased MIF protein levels (p = 0.027, 2.4 Fold
Increase) in preeclamptic PDMSCs media explants relative to
both untreated controls and explants treated with normal
PDMSCs CM (Figure 4B, left upper and lower panels). VEGF
mRNA expression was significantly increased in both PE and
normal PDMSCs CM explants relative to untreated controls
(p,0.01, 2.5 Fold Increase, Figure 4A, left panel). In stark
contrast to mRNA data, only normal PDMSCs conditioned
media was able to induce a significant VEGF protein
accumulation (p,0.01, 35 Fold increase) relative to both
untreated and PE PDMSCs CM explants (Figure 4B, right
upper and lower panels). These findings were confirmed also by
ELISA assay. Indeed, we found significantly increased VEGF
protein concentration in normal PDMSCs CM-treated explants
relative to both untreated controls (p,0.01, 1.4 Fold Increase)
and PE-PDMSCs CM-treated explants (p,0.01, 1.6 Fold
Increase) (Figure S3B, right panel). Anti-angiogenic sFlt-1 is
the main responsible for VEGF down regulation during
preeclampsia. Herein, we found significantly increased sFlt-
1 mRNA expression in PE PDMSCs CM explants relative to
both normal PDMSCs CM explants and untreated controls
(p,0.001, 2.4 and 1.5 Fold Increase respectively; Figure 4C left
panel). Data were confirmed at the protein levels, where we
reported significantly increased sFlt-1 levels in explants treated
by PE PDMSCs CM relative to both normal PDMSCs CM and
untreated control explants (p = 0.003, 2.3 and 1.4 Fold Increase
respectively; Figure 4C right upper and lower panels). Finally,
we reported significantly increased expression of Ki67, marker
of cell proliferation, in chorionic villous explants treated by PE
PDMSCs media (p = 0.044, 4.8 Fold Increase) compared to
normal PDMSCs CM explants and untreated controls
(Figure 5B, left panel). The pro-inflammatory profile of PE-
PDMSC CM explants was further confirmed by significantly
increased TNF-a protein levels relative to both normal
PDMSCs CM explants (p,0.01, 4.25 Fold Increase) and
Figure 1. Cell proliferation rate in Normal and PE-PDMSCs. Cell
proliferation in Normal and PE-PDMSCs was assessed by MTT assay at
time 0, 48 and 120 hours of culture. Results are expressed as means 6
SE of six independent samples. Statistical significance has been
considered as p,0.05. (*) = statistical significance among Normal
PDMSCs time points; (**) = statistical significance between Normal and
PE-PDMSCs at 120 hours of culture. (ns) = not statistically significant,
referred to comparisons among PE PDMSCs time points.
doi:10.1371/journal.pone.0059403.g001
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untreated controls (p = 0.014, 1.87 Fold Increase) as detected by
ELISA assay (Figure S3B left panel).
Villous explants are representative of the whole placental tissue
and composed of trophoblast, mesenchymal and endothelial cells.
Thus, we investigated the contribution of these cell populations to
the above mentioned results by determining the expression of Cyt7
(trophoblast marker), CD45 (haematopoietic/endothelial cell
marker) and CD166 (MSCs marker) in our experimental model.
Cyt7 was strongly expressed without differences in untreated,
normal and PE PDMSCs CM explants (p,0.05, Figure 5B right
upper panel). In contrast, CD45 and CD166 were barely
detectable (Figure 5B right middle and lower panels), thus
indicating that trophoblast cells were the main villous explants
cellular component.
Increased Release of Free bhCG by Villous Explants
Treated with PE PDMSCs Conditioned Media
In order to further characterize the preeclamptic-like phenotype
induced by PE PDMSCs conditioned media, we compared the
amount of free bhCG, well recognized PE biomarker [28,29],
released by normal and PE PDMSCs CM explants. We found
significantly increased bhCG mRNA levels in PE relative to
normal PDMSCs CM explants (p = 0.01, 7.45 Fold Increase,
Figure 2. Senescence quantification in PDMSCs isolated from normal and preeclamptic placentae. (A) Normal (left panel) and PE (right
panels) PDMSCs representative images after SAb-gal nuclear staining. EB: Embryoid Body. White Arrows indicate blu nuclei positive for SAb-gal
staining, indicative of cellular senescence. (B) Quantitative analysis of cellular senescence in Normal and PE-PDMSCs. For quantitative analysis, SAb-gal
positive cells were considered to be senescent cells. The percentages of senescent cells after 48 h of incubation were determined in Normal and PE-
PDMSCs populations. At least 200 cells were counted in each group. Results are expressed as means 6 SE of six independent samples. Statistical
significance (*) has been considered as p,0.05.
doi:10.1371/journal.pone.0059403.g002
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Figure 3. Expression of pro-inflammatory cytokines, chemokines and growth factors in control and PE PDMSCs conditioned media.
A) Scatter plot showing increased release in the culture media of pro-inflammatory cytokines and chemokines (80 molecules analyzed) by PE relative
to control PDMSCs. Each data point represent the average of four control media from normal PDMSCs (white squares) and four PE PDMSCs media
(black squares) used for the analysis. B) Representative cytokine array blots of unconditioned media (upper panel) and media conditioned by control
(middle panel) and PE (lower panel) PDMSCs.
doi:10.1371/journal.pone.0059403.g003
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Figure 5A left panel). Importantly, immunofluorescent assay
confirmed mRNA results revealing significantly increased free
bhCG levels (p = 0.03, 1.6 Fold Increase) in media from PE
PDMSCs CM explants relative to controls (Figure 5A right panel).
Discussion
Preeclampsia is a multi-factorial placenta-related syndrome [3]
which anomalies originate early on during the first stages of
placenta development. One of the most recognized theories
describes the poor placentation typical of PE as the result of
deficient mother-trophoblast immune acceptance [30]. This
pathological condition will lead to diminished placenta perfusion
Figure 4. MIF, VEGF and sFlt-1 expression in physiological placental villous explants treated with culture media conditioned by
normal or preeclamptic PDMSCs. MIF (A), VEGF (B) and sFlt-1 (C) mRNA (left panels) and protein (right panels) expression levels in physiological
villous explants treated with unconditioned media [C] or media conditioned by normal [N-cm] and preeclamptic [PE-cm] PDMSCs as assessed by Real
Time PCR and Western Blot analysis. Statistical significance (*) has been considered as p,0.05.
doi:10.1371/journal.pone.0059403.g004
Figure 5. bhCG and Ki 67 expression in physiological placental villous explants treated by normal or PE PDMSCs conditioned
media. A) bhCG mRNA (left panel) and free bhCG protein (right panel) levels in physiological villous explants treated with unconditioned [C], normal
[N-cm] or preeclamptic [PE-cm] PDMSC conditioned media; B) Ki67 protein expression levels (left panel) in villous explants treated under the above
mentioned experimental conditions. Figure B-right panel shows representative Western Blots for the characterization of villous explants cellular
components: Cyt7 (trophoblast cell marker), CD45 (haematopoietic/endothelial cell marker) and CD166 (mesenchymal stromal cells marker).
Statistical significance (*) has been considered as p,0.05.
doi:10.1371/journal.pone.0059403.g005
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and oxidative stress [31,32,33,34,35], increased trophoblast
apoptosis and turnover [36,37,38,39,40], release of pro-inflam-
matory cytokines and syncitiotrophoblast debris into the maternal
circulation that directly damage the endothelium [41] However,
the precise pathogenic events leading to preeclampsia still remain
unclear.
In the present study, we reported aberrant release of pro-
inflammatory cytokines by mesenchymal stromal cells derived
from preeclamptic placentae relative to normal PDMSCs.
Moreover, we described a slow proliferation rate accompanied
by increased senescence in PE-PDMSCs, suggesting a compro-
mised self-renewal capacity of these cells resident in the villous
stroma. Such a defect could significantly contribute to the aberrant
villous architecture typical of PE placentae and it is in stark
contrast with the well established hyper-proliferative phenotype of
the neighboring PE trophoblast.
Importantly, we demonstrated for the first time to our
knowledge that conditioned media from PE-PDMSCs induces a
preeclamptic-like phenotype in normal placental villous explants.
PE-PDMSC media promoted the expression of pro-inflammatory
MIF and anti-angiogenic sFlt-1 in normal term villous explants
while, at the protein level, it induced VEGF down regulation.
The discovery of such unique cells as MSCs resident in the
placental tissues (basal plate, amnion and decidua) brought us to
the hypothesis that MSCs themselves could contribute to the
pathophysiology of placentation in virtue of their immune-
regulatory and anti-inflammatory properties. MSCs exert an
immunosuppressive effect on T-cells [11] and secrete paracrine
factors that act on vasculogenesis and protect against ischemic
injury [42]. Herein, we analyzed by cytokine array technology the
expression of eighty different cytokines and growth factors in
MSCs isolated from the chorionic villous portion of normal and
PE placentae. We investigated this specific MSCs population
because it localizes in the villous mesenchyme, thus being able to
interact with the neighboring trophoblast, mesenchyme and
endothelial cells.
Overall, we found higher expression of inflammatory molecules
in media conditioned by PE relative to normal PDMSCs. In
particular, preeclamptic PDMSCs released considerably elevated
levels of IL-8, TGF-b2, TIMP-2, Osteoprotegerin, MCP-1,
Osteopontin and, to a lesser extent, IL-6, TIMP-1, ENA-78,
VEGF, Angiogenin, IGFBP-4, BDNF, LIF, IP10, PDGF-BB,
MCP-3, TARC, TNF-a, Leptin and PlGF.
Hwang and colleagues recently characterized cytokine produc-
tion profiles of MSCs isolated from amnion and decidua of healthy
versus preeclamptic placentae [43]. Interestingly, they didn’t find
differences in cytokines expression between normal and PE
amnion-derived MSCs [43] while they reported higher levels of
SDF-1 and no differences in MCP-1 expression in normal relative
to PE decidual MSCs. Their results differ from our data most
likely because we analyzed a different MSCs population isolated
from the placental villi instead of the amnion or the decidua. In
PE-PDMSCs media, we found increased levels of MCP-1 and
MCP-3, type I inflammatory chemokines able to recruit mono-
cytes, memory T cells, eosinophils and dendritic cells
[44,45,46,47]. During physiological early pregnancy, MCP-1 is
produced by first trimester extravillous trophoblast cells following
TNF stimulation [48], whereas MCP-3 is down-regulated through
peri- and post-implantation stages to let the blastocyst invade and
get acquainted to the uterine environment [49]. The aberrant
release of Th1 cytokines (cell-mediated immune response) MCP-1
and/or MCP-3 by PE-PDMSCs is indicative of a failure in the
Th2 (humoral immunity) switch typical of physiological pregnan-
cies, necessary for the correct placental immune-acceptance by the
maternal system.
In line with our results, Szarka and colleagues [50] reported
increased levels of pro-inflammatory IL-8, IL-6, IP10, TNF-a and
MCP-1 in serum from preeclamptic patients. This cytokines
profile was indicated as an hallmark of abnormal pro-inflamma-
tory systemic environment [50]. The increased release of these
molecules by PE-PDMSCs could have important pathological
implications. IL-8 is a potent chemoattractant for neutrophils
while IL-6 has a key role in the acute-phase response [51]. IP-10 is
a pro-inflammatory and anti-angiogenic cytokine that has been
proposed to link inflammation and anti-angiogenesis in pre-
eclampsia [52]. TNF-a is a type I cytokine promoter of cellular-
mediated immune response that was previously reported as over-
expressed in PE placentae and maternal serum [53,54]. TNF-a
inhibits trophoblast cell mobility in vitro [55] and it reduces
trophoblast invasive capacity [56,57,58]. Our data suggest that
PE-PDMSCs could directly affect trophoblast invasivity via TNF-
a release. Moreover, TNF-a promotes the expression of several
inflammatory molecules, thus inducing a vicious pro-inflammatory
loop detrimental for pregnancy physiology.
Other molecules abundantly over-expressed in PE-PDMSCs
media are TGF-b2, TIMP-2, Osteoprotegerin and Osteopontin.
Transforming Growth Factor-bs have been indicated as main
regulators of trophoblast invasion [59,60]. Moreover, TGF-b1
[61,62], TGF-b2 [63] and TGF-b3 [60] have been found
increased in the maternal circulation and placental tissue of PE
and FGR pregnancies, suggesting a role for TGF-bs in the
trophoblast dysfunction typical of placenta-related pathologies.
Herein, we found elevated levels of TGF-b2 and, to a lesser extent,
TGF-b1 and TGF-b3 in the conditioned media of PE-PDMSCs,
thus indicating a contribution of mesenchymal TGF-bs, TGF-b2
in particular, in PE dysfunction.
TIMPs are matrix metalloproteinase inhibitors that suppress
proliferation of endothelial cells, thus exerting an anti-angiogenic
activity. TIMP-2 has a key role during pregnancy in maintaining
the homeostasis of trophoblast invasivity. Thus, TIMP-2 expres-
sion is low during the first stages of pregnancy, to increase with
advancing gestation [64]. In accordance to our results, TIMP-2
immunoreactivity was previously found increased in syncitiotro-
phoblast and mesenchymal cells of PE placentae [65]. Data
obtained in COMT knockout mice model, suggested that
overproduction of both TIMP-2 and TGF-b3 may result in
shallow utero-placental circulation and in the onset of a
preeclamptic-like phenotype [65,66].
Osteoprotegerin (OPG) inhibit bone resorption, regulates
vascular integrity [67,68], stimulates proliferation, inflammation
and fibrogenesis in vascular smooth muscle cells [69]. The human
placenta is considered the main source of OPG during gestation
[70]. A significant increase in serum OPG concentration was
observed during pregnancy [71] and, according to our data
obtained on PE PDMSCs, placental and circulating OPG levels
further increase in preeclampsia [72]. Osteopontin (OPN) is
involved in adhesion and signal transduction at the uterine-
placental interface during implantation and placentation [73].
Importantly, OPN acts as a pro-inflammatory Th1 type cytokine
in vivo [74] and preeclamptic patients with extensive endothelial
injury are characterized by increased plasma levels of OPN [75].
Thus, the increased OPN production by PE-PDMSCs that we
reported could cause and/or further contribute to the aberrant
placental inflammation underlying preeclampsia.
PE-PDMSCs expressed also higher levels of pro-angiogenic
growth factors VEGF, Angiogenin and PlGF. Besides being
pivotal for placentation, these angiogenic molecules can be strong
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endothelial cell activators. VEGF role in PE pregnancy has been
controversially discussed, as its levels in PE maternal serum have
been reported as increased [76,77,78], decreased [79,80], or even
unchanged [81] Angiogenin expression in the human placenta
increases during gestation [82] and it is further up-regulated in
fetal growth restricted pregnancies relative to controls [83].
Placental Growth Factor (PlGF) expression is limited to the
placental tissue where it promotes villous angiogenesis during early
gestation. PlGF plasma levels and function are dramatically
compromised in PE patients, resulting in endothelial injury and
vascular permeability [22]. Indeed, increased PlGF expression by
PE-PDMSCs could also indicate a compensatory mechanisms
acted to induce new angiogenesis in the compromised PE
placental vasculature.
Leptin, LIF, PDGF-BB and BDNF are as well augmented in
PE-PDMSCs relative to control PDMSCs media. During preg-
nancy, these cytokines are involved in critical processes as
placental invasion [84], trophoblast cell proliferation, fetal growth
and development [84,85]. Moreover, they stimulates cytokines
production [84] and are directly implicated in inflammation [85],
suggesting a pathophysiological role in preeclampsia. Leptin and
LIF have been previously reported to be over-expressed at both
placental and plasma levels in severe preeclamptic pregnancies
[86,87]. Leptin, in particular, could aggravate hypertension and
endothelial damage by promoting catecholamine production [86].
On the other hand, PDGF-BB is a potent chemoattractor that
drives mesenchymal cells migration [88], thus its increase in PE-
PDMSCs media could be interpreted as an attempt to recruit
MSCs and repair placental damage.
Taken together, our data clearly indicate that preeclamptic
MSCs resident in the chorionic placental villi over-produce a
repertoire of cytokines, chemokines and growth factors that could
directly contribute to the anomalies of trophoblast development
and placental angiogenesis and to the exacerbated inflammatory
response typical of PE and FGR. These molecules, crucial for
proper pregnancy outcome under normal conditions, when
abnormally expressed are detrimental for placenta physiology. In
line with our results, Waterman and colleagues described two
different immune-modulating profiles in human MSCs isolated
from bone marrow. They found pro-inflammatory Toll-like
Receptor 4 (TLR4) primed MSCs, that expressed high levels of
IL-8, IL-6 and TGF-b2 molecules, and immunosuppressive
TLR3-primed MSCs, characterized by marked expression of IL-
4. IL-10, RANTES and IP-10 [89]. We reported significantly
increased levels of IL-8, IL-6 and TGF-b2 cytokines in
preeclamptic placental MSCs relative to controls, thus indicating
that PE PDMSCS resemble a pro-inflammatory TLR4-primed
phenotype.
Therefore, we next investigated whether PE-PDMSCs could alter
the physiological placental equilibrium. We treated normal chori-
onic villous explants with media conditioned by normal or PE
PDMSCs and investigated the expression of MIF, VEGF, sFlt-1,
Ki67 and bhCG molecules. MIF is a central regulator of
inflammation and immune response [90] described in both villous
and extravillous trophoblast in humans [91,92]. Emerging evidences
emphasize its importance in early pregnancy, embryonic develop-
ment and preeclampsia [19,91,92,93]. Herein, we found that
normal villous explants treated with PE PDMSCs conditioned
media over-expressed MIF at both gene and protein levels, while
CM from normal PDMSCs did not affect physiological MIF
production. Our group previously reported that MIF serum levels
were significantly increased in women affected by severe PE [19,93],
thus entailing a role for MIF in the etiopathogenesis of PE.
Importantly, TNF-a, beside being directly induced by MIF,
promotes MIF production by a positive feedback [94]. Indeed, the
high TNF-a levels secreted by PE PDMSCs could explain MIF
mRNA and protein accumulation. This PE-PDMSCs induced
alteration in MIF expression further confirm the contribution of
pathological mesenchymal stromal cells to the pathogenesis of
preeclampsia.
As discussed above, VEGF orchestrates angiogenesis and it is
vital for early embryonic development [95]. VEGF is involved
also in the pathogenesis of preeclampsia. The preeclamptic
placenta over-expresses VEGF in response to the hypoxic
environment [21,96], but free and biologically active VEGF
protein is sequestered and down-regulated by sFlt-1, soluble
variant of VEGF receptor 1 released in excess by the PE
placenta [22,23,24,25]. In the present study, both normal and
preeclamptic PDMSCs’s media promoted VEGF mRNA
expression compared to untreated chorionic villous explants,
while only PE PDMSCs media induced sFlt-1 mRNA accumu-
lation. In accordance to mRNA data, normal PDMSCs’s media
treatment was accompanied by VEGF protein accumulation,
thus confirming the well documented pro-angiogenic activity of
mesenchymal stromal cells [42]. In stark contrast, treatment
with PE PDMSCs’s media resulted not in VEGF but in sFlt-1
protein increase. Our results resemble the in vivo condition
typical of preeclampsia, where the VEGF placental mRNA
increase induced by the hypoxic and pro-inflammatory envi-
ronment is antagonized by the over-expression of anti-angio-
genic sFlt-1.
Moreover, preeclamptic placentae are characterized by imma-
ture hyper-proliferative trophoblast phenotype. Thus, we investi-
gated Ki67 expression in villous explants treated by normal or PE
PDMSCs conditioned media. We reported significant Ki67in-
crease in PE-PDMSCs CM explants, indicating the induction of
an hypertrophic PE-like status by preeclamptic PDMSCs.
As a further confirmation of the PE-like environment provoked
by PE-PDMSCs, we reported augmented release of free bhCG by
normal villous explants treated with preeclamptic PDMSCs
media. hCG is normally secreted by trophoblast cells to maintain
maternal vascular supply during pregnancy and its increased
circulating levels have been associated with a dramatically higher
risk of developing preeclampsia [28,29].
We are currently investigating whether normal placental MSCs
are able to revert the pathological inflammatory conditions typical
of PE placentae.
In conclusion, our data clearly depict chorionic placental
mesenchymal stromal cells as central players in placental
physiopathology, thus opening to new intriguing perspectives for
the treatment of human placental-related disorders as preeclamp-
sia and fetal growth restriction.
Supporting Information
Figure S1 Placenta-derived Mesenchymal Stromal Cells
Characterization. A) Representative phenotype of human
chorionic PDMSCs at passage 5 as assessed by flow cytometry.
All cells were positive for CD166, CD105, CD90, CD73 and
negative for HLA II, CD34, CD133, CD20, CD326, CD31,
CD45 and CD14, thus displaying proper mesenchymal profile and
no contamination from epithelial, hematopoietic, immune or
endothelial cells. B) Representative Oct4 and Nanog PCR analysis
in control and PE PDMSCs. All cell lines expressed both gene
markers of stemness.
(TIF)
Figure S2 Gene expression levels of key differentially
expressed molecules detected by Cytokine Array in
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normal (C) and preeclamptic (PE) PDMSCs. MIF (A),
VEGF (B), TNF-a (C), IL-8 (D) and IL-6 (E) mRNA expression
levels in normal and PE-PDMSCs as assessed by Real Time PCR.
Statistical significance (*) has been considered as p,0.05.
(TIF)
Figure S3 TNF-a and VEGF protein expression in
Normal and PE-PDMSCs Conditioned Media and in
physiological placental villous explants treated by
normal or PE PDMSCs CM as detected by ELISA Assay.
(A) TNF-a (left panel) and VEGF (right panel) protein levels in
media conditioned by Normal [N-cm] or preeclamptic [PE-cm]
PDMSCs. (B) TNF-a (left panel) and VEGF (right panel) protein
levels in untreated control explants [C] and explants treated by
normal [N-cm] and preeclamptic [PE-cm] PDMSCs conditioned
medium. Results are expressed as means 6 SE. Statistical
significance (*) has been considered as p,0.05.
(TIF)
Table S1 Cytokines Expression in Normal vs Pre-
eclamptic PDMSCs Conditioned Media.
(DOC)
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